Freed's Standalone Adoption Advantage

Freed’s standalone design is the core reason it can grow bottom up in a market where most rivals need enterprise permission first. A solo doctor or small practice can start using it like any other SaaS tool, record the visit, get a structured note in about a minute, and paste that note into the EHR without waiting for a hospital IT team, a formal rollout, or a deep integration project.

• The economic contrast is stark. Freed sells for $99 per month per clinician, versus human scribes that can cost $40K per year and enterprise AI scribes that often charge several hundred dollars per month per seat. That makes the purchase decision small enough for an individual clinician to make alone.
  1 sacra 2 sacra 3 sacra
• This is the opposite of the Abridge model. Abridge won by going deep with Epic and large health systems, which helped it reach 60,000 plus clinicians and about $100M ARR by May 2025, but that path depends on EHR partnerships, procurement, and integration depth. Freed instead reached 17,000 clinicians and about $19M ARR by March 2025 through self serve adoption.
  2 sacra 4 sacra
• Standalone is powerful, but it is also a wedge, not the endpoint. In small practices, copy and paste is good enough to prove value fast. Over time, the harder work is turning that initial note product into deeper workflows like pre charting, coding, and EHR actions, where bigger systems care less about the note itself and more about eliminating every admin click after the visit.
  2 sacra 3 sacra

The path forward is clear. The companies that start as lightweight note tools will keep moving closer to the system of record, and the winners will be the ones that turn a fast standalone entry point into deeper workflow control. Freed is well positioned if it can convert individual clinician love into broader practice level adoption and then into more embedded documentation and revenue cycle tasks.